



Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

Hani M. Babiker¹ · Mohammed Milhem² · Joseph Aisner³ · William Edenfield⁴ · Dale Shepard⁵ · Michael Savona⁶ · Swaminathan Iyer⁷ · Maen Abdelrahim⁸ · C. L. Beach⁹ · Barry Skikne^{9,10} · Eric Laille⁹ · Kao-Tai Tsai⁹ · Thai Ho¹¹

Published online: 25 March 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

**Correction to: Cancer Chemotherapy and Pharmacology
(2020) 85:621–626**
<https://doi.org/10.1007/s00280-020-04037-9>

In the original publication of the article the author has found few incorrect values in the Table 1. The corrected Table 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s00280-020-04037-9>.

✉ Hani M. Babiker
hanibabiker@email.arizona.edu

¹ University of Arizona Comprehensive Cancer Center,
Tucson, AZ, USA

² University of Iowa Hospital, Iowa City, IA, USA

³ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
USA

⁴ Greenville Health System, Greenville, SC, USA

⁵ Cleveland Clinic, Cleveland, OH, USA

⁶ Vanderbilt University Medical Center, Nashville, TN, USA

⁷ MD Anderson Cancer Center, Houston, TX, USA

⁸ Houston Methodist Hospital, Houston, TX, USA

⁹ Celgene Corporation, Summit, NJ, USA

¹⁰ University of Kansas Medical Center, Kansas City, KS, USA

¹¹ Mayo Clinic, Phoenix, AZ, USA

Table 1 Food effect on the plasma pharmacokinetic parameters of the CC-486 300 mg Formulation B tablet

Condition	Statistic	AUC _t (ng h/mL)	AUC _∞ (ng h/mL)	C _{max} (ng/mL)	T _{max} (h)	t _{1/2} (h)	CL/F (L/h)	Vz/F (L)
Fasted	<i>N</i>	56	54	56	56	54	54	54
	Geometric Mean ^a	224.9	234.5	131.7	NA	0.58	1280	1074
	Geometric %CV	68.4	62.9	70.4	NA	31.6	62.9	76.2
	Median	240	243	141	1.0	0.55	1230	1140
	Min, max	41.5, 1050	65.9, 1050	21.4, 608	0.50, 4.0	0.35, 1.7	286, 4550	228, 6310
Fed	<i>N</i>	55	44	55	55	46	44	44
	Geometric Mean ^a	233.7	248.9	105.2	NA	0.78	1205	1279
	Geometric %CV	58.3	52.0	76.3	NA	55.2	52.0	80.5
	Median	250	250	116	2.0	0.68	1200	1160
	Min, Max	61.3, 554	78.9, 560	22.7, 337	0.50, 6.1	0.40, 6.2	536, 3800	399, 9350
PK parameter	Condition	<i>N</i>	Geometric mean [†]	Ratio (%) of geometric means	90% CI of ratio (%) of geometric means	Intra-patient %CV		
AUC _t (ng h/mL)	Fasted	56	227.8	101.7	(92.83, 111.5)	29.0		
	Fed	55	231.8					
AUC _∞ (ng h/mL)	Fasted	54	237.5	108.9	(98.48, 120.5)	28.3		
	Fed	44	258.7					
C _{max} (ng/mL)	Fasted	56	133.0	78.86	(68.58, 90.68)	45.5		
	Fed	55	104.9					
PK parameter	Condition	<i>N</i>	Median	Median difference	90% CI of median difference (Fed–fasted)	<i>P</i> value		
T _{max} (h) [‡]	Fasted	56	1.0	1.0	(0.75, 1.3)	<0.001		
	Fed	55	2.0					

N patients = the total number of patients for which the PK parameter could be calculated. AUC_∞, t_{1/2}, CL/F, and Vz/F could not be calculated in some instances, if there were not data from a sufficient number of time points after the occurrence of C_{max}

Slight differences in geometric means of AUC_∞ and C_{max} are due to different methods of calculation

AUC_t area under the plasma concentration–time curve from time 0 to time *t*, AUC_∞ area under the plasma concentration–time curve from time 0 extrapolated to infinity, C_{max} maximum plasma concentration, T_{max} time to C_{max}, t_{1/2} terminal half-life, CL/F apparent total clearance, Vz/F volume of distribution, NA not applicable

[†]Calculated using an analysis of variance (ANOVA) model

[‡]Median and median difference (Test vs. Reference), and 90% CI of the median difference, are from Hodges-Lehmann estimate. The *P* value is from Wilcoxon signed-rank test

^aCalculated using summary statistics.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.